ReviewJournal of translational medicine2026
Emerging regulatory model of Ubiquitin-Specific Proteases 14 in cancer: from canonical oncogenesis to TME modulation, therapeutic resistance, and non-canonical activities.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUbiquitin-Specific Protease 14 (USP14) is a proteasome-associated deubiquitinase historically viewed as a pro-tumorigenic driver of the ubiquitin-proteasome system (UPS) by stabilizing oncoproteins. Recent evidence expands this view, positioning USP14 as a central regulator that integrates tumor cell-intrinsic malignancy, tumor microenvironment (TME) remodeling, and resistance to multiple therapies. Importantly, USP14 exerts functions beyond canonical deubiquitination, including non-catalytic and scaffolding activities, and is subject to complex allosteric regulation. MAIN BODY: This review synthesizes emerging regulatory crosstalks that broaden the functional landscape of USP14 in cancer. We first outline the dynamic allosteric regulatory network of USP14 and its activation modes, emphasizing post-translational modifications (PTMs)-notably phosphorylation and lactylation-that modulate USP14 activity and connectivity beyond traditional links to cell cycle control and metabolism. We then consolidate the signaling frameworks through which USP14 contributes to resistance across therapeutic modalities, including targeted therapies, chemotherapy, radiotherapy, and immunotherapy, highlighting both shared and treatment-specific mechanisms. In parallel, we discuss context-dependent tumor-suppressive roles of USP14 and detail its non-catalytic scaffolding functions that reshape signaling outputs independent of enzymatic activity. Collectively, these classical and non-classical mechanisms depict USP14 as a systems-level coordinator of oncogenic signaling, adaptive stress responses, and microenvironmental interactions.
conclusionsBy integrating catalytic and non-catalytic functions with PTM-driven allosteric regulation, we propose a unified regulatory model in which USP14 operates as a master node connecting malignancy, TME dynamics, and therapeutic resistance. This framework provides strategic guidance for developing next-generation allosteric inhibitors and combination strategies aimed at overcoming clinical drug resistance and exploiting context-specific vulnerabilities in USP14-regulated networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.